Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) traded down 4.8% on Monday . The company traded as low as $9.48 and last traded at $9.37. 330,679 shares changed hands during trading, a decline of 89% from the average session volume of 3,135,493 shares. The stock had previously closed at $9.84.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, January 31st. JPMorgan Chase & Co. lifted their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research note on Thursday, January 9th. Barclays lowered their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Needham & Company LLC restated a "buy" rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Finally, Leerink Partners raised their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $34.83.
View Our Latest Analysis on Vir Biotechnology
Vir Biotechnology Price Performance
The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -2.46 and a beta of 0.64. The business's fifty day simple moving average is $9.13 and its 200 day simple moving average is $8.48.
Insider Activity
In other news, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the transaction, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 12,598 shares of company stock worth $152,136 over the last three months. 15.60% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Artisan Partners Limited Partnership purchased a new position in Vir Biotechnology during the fourth quarter worth about $6,742,000. Dimensional Fund Advisors LP boosted its holdings in Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock worth $14,059,000 after purchasing an additional 703,360 shares during the last quarter. State Street Corp boosted its holdings in Vir Biotechnology by 10.4% during the third quarter. State Street Corp now owns 5,625,533 shares of the company's stock worth $42,135,000 after purchasing an additional 530,645 shares during the last quarter. Alta Partners Management Company L.P. purchased a new position in Vir Biotechnology during the fourth quarter worth about $3,593,000. Finally, Walleye Capital LLC raised its position in Vir Biotechnology by 2,119.4% in the fourth quarter. Walleye Capital LLC now owns 434,460 shares of the company's stock worth $3,189,000 after acquiring an additional 414,884 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Further Reading
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
